Search results for Crizanlizumab

Crizanlizumab, Abbexa, abx831409

Crizanlizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SELP, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Crizanlizumab ELISA Kit, Abbexa, abx395080

Crizanlizumab ELISA Kit is a quantitative ELISA kit for detection of Crizanlizumab.Crizanlizumab is a humanized monoclonal antibody directed against P-selectin that showed effectiveness in preventing VOC induced pain crises. Median rate of pain crises was 1.63 in crizanlizumab treated group versus 2.998 in placebo group. Furthermore, the median time to crisis was 4.07 months with crizanlizumab compared to 1.38 in the placebo group. The benefits of treatment held true within subgroups including those with a high number of VOC prior to treatment and those with more severe genotype. The drug is FDA approved to reduce the frequency of VOC in adults and pediatric patients with SCD aged 16 years and older.

Crizanlizumab Biosimilar - Research Grade, ichor.bio, ICH5300

Detects human SELP

Research Grade Crizanlizumab (HB885016), abinScience, HB885016